Exforge HCT

Exforge HCT Drug Interactions

Manufacturer:

Novartis

Distributor:

Zuellig
Full Prescribing Info
Drug Interactions
No formal interaction studies with other medicinal products were performed with Exforge HCT. Thus, only information on interactions with other medicinal products that are known for the individual active substances is provided in this section.
However, it is important to take into account that Exforge HCT may increase the hypotensive effect of other antihypertensive agents.
Concomitant use not recommended: See Table 2.

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

Dual blockade of the RAAS with ARBs, ACE inhibitors or aliskiren: Clinical trial data have shown that dual blockade of the RAAS through the combined use of ACE inhibitors, ARBs or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent.
The concomitant use of ARBs-including valsartan-or of ACE inhibitors with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) (see Contraindications and Precautions).
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in